Published in Arch Pathol Lab Med on November 01, 2011
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17
PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano (2012) 1.15
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging (2014) 0.89
Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One (2015) 0.85
Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjug Chem (2014) 0.82
Cancer stratification by molecular imaging. Int J Mol Sci (2015) 0.78
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials (2015) 0.75
Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med (2016) 0.75
MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound. Mol Imaging Biol (2017) 0.75
Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget (2017) 0.75
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics. Sci Rep (2017) 0.75
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Parthenogenetic stem cells in nonhuman primates. Science (2002) 2.54
Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A (2006) 2.51
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 2.27
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
The hidden treasure in apical papilla: the potential role in pulp/dentin regeneration and bioroot engineering. J Endod (2008) 1.95
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol (2010) 1.80
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol (2008) 1.73
Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol (2010) 1.70
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Microglia in diseases of the central nervous system. Ann Med (2002) 1.66
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest (2007) 1.66
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 1.61
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol (2005) 1.54
Subdural hematoma in patients with cancer. Neurosurgery (2012) 1.54
Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol (2009) 1.53
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery (2005) 1.51
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Multifocal stroke from tumor emboli. Arch Neurol (2009) 1.48
Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet (2013) 1.45
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg (2011) 1.40
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
Recombinant mouse hepatitis virus strain A59 from cloned, full-length cDNA replicates to high titers in vitro and is fully pathogenic in vivo. J Virol (2005) 1.36
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol (2003) 1.31
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) (2011) 1.30
First Cu(II) diamondoid net with 2-fold interpenetrating frameworks. The role of anions in the construction of the supramolecular arrays. Inorg Chem (2002) 1.29
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys (2006) 1.22
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res (2003) 1.22
Molecular mechanisms underlying the analgesic property of intrathecal dexmedetomidine and its neurotoxicity evaluation: an in vivo and in vitro experimental study. PLoS One (2013) 1.21
Effect of brain tumor neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex. Neuroimage (2006) 1.21
Diffusion-tensor MR tractography of somatotopic organization of corticospinal tracts in the internal capsule: initial anatomic results in contradistinction to prior reports. Radiology (2005) 1.20
Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. Cell Res (2011) 1.19
Genome sequence of Stenotrophomonas maltophilia RR-10, isolated as an endophyte from rice root. J Bacteriol (2012) 1.18
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 1.16
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Multinodular and vacuolating neuronal tumors of the cerebrum: 10 cases of a distinctive seizure-associated lesion. Brain Pathol (2013) 1.13
Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve (2004) 1.12
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery (2009) 1.10
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med (2005) 1.10
Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep (2011) 1.10
Meningioma resection in the elderly: nationwide inpatient sample, 1998-2002. Neurosurgery (2005) 1.08
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res (2005) 1.08
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Genome sequence of the rice-pathogenic bacterium Acidovorax avenae subsp. avenae RS-1. J Bacteriol (2011) 1.07
Real-time ultrasound elastography: its potential role in assessment of breast lesions. Ultrasound Med Biol (2008) 1.07
The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J (2010) 1.06
Anterior cranial base reconstruction using free tissue transfer: changing trends. Head Neck (2003) 1.04
Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol (2008) 1.03
Convection-enhanced delivery into the rat brainstem. J Neurosurg (2002) 1.03
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm (2016) 1.02
Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res (2003) 1.02
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell (2007) 1.02
Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotact Funct Neurosurg (2006) 1.02
Associations and impact factors between living arrangements and functional disability among older Chinese adults. PLoS One (2013) 1.01
Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res (2009) 0.99
Real-time PCR assays targeting formyltetrahydrofolate synthetase gene to enumerate acetogens in natural and engineered environments. Anaerobe (2009) 0.98
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol (2012) 0.98
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate (2004) 0.98
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) (2012) 0.97
Patterning, characterization, and chemical sensing applications of graphene nanoribbon arrays down to 5 nm using helium ion beam lithography. ACS Nano (2014) 0.97
Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol (2007) 0.96
(6,6-Dimethyl-1-phenyl-6,7-di-hydro-5H-pyrrolizin-2-yl)(thio-phen-2-yl)methanone. Acta Crystallogr Sect E Struct Rep Online (2013) 0.96
Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett (2008) 0.95
Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev (2005) 0.95
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate (2010) 0.95
Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma. AJNR Am J Neuroradiol (2004) 0.95
Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018). Bioorg Med Chem Lett (2005) 0.95
Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res (2007) 0.95
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther (2005) 0.94
Surgery of brain metastases--is there still a place for it? J Neurooncol (2005) 0.93
Amino acid substitutions within the heptad repeat domain 1 of murine coronavirus spike protein restrict viral antigen spread in the central nervous system. Virology (2003) 0.93
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol (2012) 0.93